A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial

•Granulosa cell tumours are rare and there are no prospective trials of hormonal therapies.•High response rates have been reported with aromatase inhibitors in case reports.•PARAGON is a prospective study of anastrozole in granulosa cell tumours.•The objective response rate was 10.5%, which is lower than reported in the literature.